323 related articles for article (PubMed ID: 16455632)
1. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET.
Kwee SA; Wei H; Sesterhenn I; Yun D; Coel MN
J Nucl Med; 2006 Feb; 47(2):262-9. PubMed ID: 16455632
[TBL] [Abstract][Full Text] [Related]
2. Use of step-section histopathology to evaluate 18F-fluorocholine PET sextant localization of prostate cancer.
Kwee SA; Thibault GP; Stack RS; Coel MN; Furusato B; Sesterhenn IA
Mol Imaging; 2008; 7(1):12-20. PubMed ID: 18384719
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography.
Kwee SA; Coel MN; Lim J; Ko JP
J Urol; 2005 Jan; 173(1):252-5. PubMed ID: 15592091
[TBL] [Abstract][Full Text] [Related]
4. Dual-phase (18)F-fluorocholine PET/CT to detect locoregional recurrence of prostate cancer: comparison between each time point of imaging and a summation scan.
Tong AK; Zhang ZX; Zaheer S; Yan XS
Clin Imaging; 2016; 40(3):486-91. PubMed ID: 27133692
[TBL] [Abstract][Full Text] [Related]
5. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
6. Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence.
Steiner Ch; Vees H; Zaidi H; Wissmeyer M; Berrebi O; Kossovsky MP; Khan HG; Miralbell R; Ratib O; Buchegger F
Nuklearmedizin; 2009; 48(1):1-9; quiz N2-3. PubMed ID: 19212605
[TBL] [Abstract][Full Text] [Related]
7. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis.
Farsad M; Schiavina R; Castellucci P; Nanni C; Corti B; Martorana G; Canini R; Grigioni W; Boschi S; Marengo M; Pettinato C; Salizzoni E; Monetti N; Franchi R; Fanti S
J Nucl Med; 2005 Oct; 46(10):1642-9. PubMed ID: 16204714
[TBL] [Abstract][Full Text] [Related]
8. Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy.
Conrad GR; Sinha P
Nucl Med Commun; 2003 Nov; 24(11):1129-37. PubMed ID: 14569166
[TBL] [Abstract][Full Text] [Related]
9. The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer.
Igerc I; Kohlfürst S; Gallowitsch HJ; Matschnig S; Kresnik E; Gomez-Segovia I; Lind P
Eur J Nucl Med Mol Imaging; 2008 May; 35(5):976-83. PubMed ID: 18188560
[TBL] [Abstract][Full Text] [Related]
10. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
[TBL] [Abstract][Full Text] [Related]
11. [Single center experience of (18F)-fluorocholine positron emission tomography: analysis of its impact on salvage local therapy in patients with prostate adenocarcinoma].
Moussaid Y; Bonardel G; Jacob J; Métivier D; Gontier E; Bauduceau O; Durand X; Fayolle M; Houlgatte A; Foehrenbach H; Védrine L; Chargari C
Cancer Radiother; 2013; 17(4):259-64. PubMed ID: 23702489
[TBL] [Abstract][Full Text] [Related]
12. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.
Beheshti M; Imamovic L; Broinger G; Vali R; Waldenberger P; Stoiber F; Nader M; Gruy B; Janetschek G; Langsteger W
Radiology; 2010 Mar; 254(3):925-33. PubMed ID: 20177103
[TBL] [Abstract][Full Text] [Related]
13. Does dual-time-point
Wu B; Zhao Y; Zhang Y; Tan H; Shi H
Hell J Nucl Med; 2017; 20(1):79-82. PubMed ID: 28315913
[TBL] [Abstract][Full Text] [Related]
14. Can dual-time-point 18F-FDG PET/CT differentiate malignant salivary gland tumors from benign tumors?
Toriihara A; Nakamura S; Kubota K; Makino T; Okochi K; Shibuya H
AJR Am J Roentgenol; 2013 Sep; 201(3):639-44. PubMed ID: 23971458
[TBL] [Abstract][Full Text] [Related]
15. [Differentiation of malignant and benign superficial lymph nodes by dual time point 18F-FDG PET].
Su MG; Fan QP; Tian Y; Li FL; Yang XC; Li L; Fan CZ; Tian R
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):517-20. PubMed ID: 19627018
[TBL] [Abstract][Full Text] [Related]
16. 18F-fluoride PET/CT for bone scanning. Role of attenuation correction.
Nagarajah J; Dannat T; Hartung V; Bockisch A; Rosenbaum-Krumme S
Nuklearmedizin; 2012; 51(3):84-7. PubMed ID: 22366817
[TBL] [Abstract][Full Text] [Related]
17. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of delayed 18F-FDG PET in differential diagnosis for malignant soft-tissue tumors.
Hamada K; Tomita Y; Ueda T; Enomoto K; Kakunaga S; Myoui A; Higuchi I; Yoshikawa H; Hatazawa J
Ann Nucl Med; 2006 Dec; 20(10):671-5. PubMed ID: 17385305
[TBL] [Abstract][Full Text] [Related]
19. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.
Schuster DM; Votaw JR; Nieh PT; Yu W; Nye JA; Master V; Bowman FD; Issa MM; Goodman MM
J Nucl Med; 2007 Jan; 48(1):56-63. PubMed ID: 17204699
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
Hashimoto Y; Tsujikawa T; Kondo C; Maki M; Momose M; Nagai A; Ohnuki T; Nishikawa T; Kusakabe K
J Nucl Med; 2006 Mar; 47(3):426-31. PubMed ID: 16513611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]